Introduction

Investing in the healthcare sector requires a delicate balance between defensive stability and growth potential. Within this space, McKesson Corporation (NYSE: MCK) has long stood as a cornerstone of the global pharmaceutical supply chain. As of late May 2026, with McKesson stock trading at approximately $766.08, investors are closely examining the giant's trajectory after its stellar Fiscal Year 2026 earnings report. While the stock has pulled back from its recent 52-week high of $999.00, the company’s underlying fundamentals tell a story of aggressive structural refinement, massive capital returns, and a bold pivot into higher-margin specialized healthcare markets.

Historically, distributors like McKesson operated as low-margin, high-volume logistical machines. However, McKesson’s deliberate transition away from commoditized retail markets toward high-growth oncology, biopharma services, and digital prescription technologies is redefining its investment narrative. In this comprehensive analysis, we will dive deep into McKesson stock, exploring its recent financial performance, landmark strategic divestitures, the multi-billion-dollar partnership with Apollo Global Management, and the ultimate risk-reward profile for long-term investors in 2026.

McKesson’s Fiscal 2026 Financial Triumph and FY27 Outlook

To truly evaluate McKesson stock, one must first unpack the sheer scale of its financial machinery. In May 2026, McKesson reported its fourth-quarter and full-year results for the fiscal year ending March 31, 2026. The results were nothing short of a masterclass in operational efficiency and disciplined execution.

For the full fiscal year 2026, McKesson generated consolidated revenues of $403.43 billion—a 12% increase compared to the $359.05 billion recorded in fiscal 2025. This top-line expansion was driven primarily by robust prescription volumes within the North American Pharmaceutical segment and explosive growth in the distribution of oncology and specialty health products. Net income for the year soared to $4.76 billion, marking a staggering 44% year-over-year increase, while adjusted earnings per diluted share (Adjusted EPS) came in at $39.11, up 18% from the previous year.

Looking closer at the fourth quarter of fiscal 2026, consolidated revenues reached $96.30 billion, up 6% year-over-year. Adjusted EPS for the quarter was $11.69, a 16% increase that beat Wall Street consensus estimates. What makes these numbers particularly impressive is that they were achieved during a period of complex restructuring, showing that McKesson can rebuild the ship while maintaining record-breaking speed.

Perhaps the most encouraging signal for investors holding or considering McKesson stock is the management’s upbeat guidance for Fiscal Year 2027. McKesson expects to deliver Adjusted EPS in the range of $43.80 to $44.60. At the midpoint of $44.20, this implies an additional 13% earnings growth on top of the spectacular fiscal 2026 performance. This guidance reflects management's confidence in their strategic growth platforms and the ongoing resilience of the core business.

McKesson's cash generation capabilities remain its crowning jewel. In fiscal 2026, the company generated $6.2 billion in cash from operations. After investing $745 million in capital expenditures, McKesson delivered free cash flow of $5.4 billion. For a business with a market capitalization of roughly $92 billion, a free cash flow yield of around 5.8% provides a massive safety cushion and an enormous war chest for capital allocation, which we will analyze later in this guide.

The Blueprint of McKesson's Strategic Overhaul

McKesson’s impressive financials are not a stroke of luck; they are the direct result of a multi-year portfolio optimization strategy. Management has made it clear that they are no longer interested in low-margin, high-friction international retail markets. Instead, they are redirecting capital to high-margin, specialized U.S. healthcare services.

Exiting European Retail: The Final Phase

On January 30, 2026, McKesson officially closed the transaction to sell its retail and distribution businesses in Norway. This divestiture marked the final phase of McKesson’s comprehensive exit from the European retail pharmacy market. By shedding these capital-intensive, highly regulated retail operations, McKesson has successfully streamlined its business model, reduced geographical exposure to European price controls, and freed up management bandwidth to focus on core growth areas in North America.

The Medical-Surgical Solutions Separation and the Apollo Partnership

One of the most significant catalysts for McKesson stock in 2026 is the planned separation of the Medical-Surgical Solutions (MMS) segment. The MMS business distributes medical-surgical supplies and equipment primarily to non-acute care settings, such as physician offices, surgery clinics, and long-term care facilities. While MMS is a highly resilient and valuable business, its growth profile differs from McKesson’s rapidly growing specialty pharmacy and oncology segments.

On April 20, 2026, McKesson announced a landmark agreement with funds managed by affiliates of Apollo Global Management. Under the terms of the agreement, Apollo is investing $1.25 billion in convertible preferred equity to acquire a 13% minority interest in the MMS business. This strategic transaction values the Medical-Surgical Solutions business at an enterprise value of approximately $13 billion.

This deal is a major win for McKesson shareholders for several reasons:

• Valuation Validation: A $13 billion valuation for MMS highlights the hidden value within McKesson’s conglomerate structure. It proves that scale distribution assets with deep-seated institutional relationships command premium multiples.
• Path to IPO: This transaction represents a critical milestone in preparing MMS for a planned initial public offering (IPO), expected in 2027. Apollo’s deep experience in complex corporate carve-outs and public market transitions will help ensure a successful standalone launch.
• Maintained Control: McKesson retains operating control and majority ownership of MMS until the final separation. It will continue to consolidate the segment’s stable financial results, minimizing any sudden drop in overall corporate earnings.

Deepening the Oncology and Specialty Care Moat

With the capital freed up from divestitures and the Apollo investment, McKesson is building an unparalleled moat in oncology and biopharma services. The US Oncology Network, which is owned and operated by McKesson, continues to expand rapidly. In April 2026, the network announced the addition of Cancer Care Northwest, further expanding its footprint in community oncology practices.

Specialty oncology distribution is significantly more profitable and has higher barriers to entry than standard generic drug distribution. Oncology drugs are highly sensitive, expensive, and require specialized cold-chain logistics and administration technologies. By integrating clinical care, specialty distribution, and biopharma commercialization services, McKesson has created a highly sticky ecosystem that competitors cannot easily replicate. In fiscal 2026, the Oncology and Multispecialty segment saw its revenue jump 35%, while its operating profit climbed an astonishing 53%, vindicating management’s aggressive pivot.

The Power of Capital Allocation: Massive Share Buybacks and Dividends

For long-term investors, the primary appeal of McKesson stock is often the company's aggressive and highly disciplined capital allocation strategy. McKesson is a cannibalistic stock in the best sense of the word—constantly buying back its own shares to supercharge per-share earnings growth.

The Power of Share Repurchases

During fiscal year 2026, McKesson returned an eye-watering $5.1 billion to shareholders. Of this total, $4.8 billion was deployed toward common stock repurchases, with the remaining $381 million paid out as dividends. In the fourth quarter of fiscal 2026 alone, the company completed $2.7 billion in share repurchases, which included a massive $2.25 billion accelerated share repurchase (ASR) program.

To ensure this momentum continues, McKesson's Board of Directors approved an additional $5.0 billion share repurchase authorization in April 2026. This brought the company's total authorized repurchases to an incredible $7.7 billion as of late spring.

Let’s put these numbers into perspective. With McKesson’s market cap hovering around $92 billion, the remaining $7.7 billion authorization represents roughly 8.3% of the outstanding shares. When a company continuously reduces its share count by 5% to 8% annually, it creates a powerful upward draft on earnings per share. Even if the net income remains completely flat, the reduced share count automatically raises the EPS, making the stock more valuable over time. This aggressive share retirement is a core reason why McKesson stock has consistently outperformed the broader S&P 500 index over multi-year horizons.

A Reliable, Growing Dividend

While McKesson is primarily an earnings-growth and share-buyback story, it is also a quiet champion of dividend growth. In August 2025, the Board approved a 15% increase to the quarterly dividend, raising it to $0.82 per share ($3.28 annualized). This marked the ninth consecutive year of dividend increases for the company.

At the current stock price of approximately $766.08, the dividend yield stands at a modest 0.43%. While income-focused investors might find this yield underwhelming, it is crucial to look at the payout ratio. With an annual payout of $3.28 against an expected fiscal 2027 adjusted EPS of $44.20, McKesson’s dividend payout ratio is an incredibly conservative 7.4%. This low payout ratio ensures that the dividend is completely safe from economic downturns and leaves massive room for double-digit annual increases for decades to come.

Understanding the Valuation and Key Investment Risks

Despite McKesson’s formidable competitive positioning and outstanding financial track record, no stock is without risk. To make an informed decision on McKesson stock in 2026, investors must weigh its current valuation against structural headwinds in the U.S. healthcare system.

Valuation in Perspective

At $766.08, McKesson stock is trading at a trailing price-to-earnings (P/E) ratio of approximately 19.9x. When utilizing the midpoint of the company’s fiscal 2027 Adjusted EPS guidance ($44.20), the forward P/E drops to an attractive 17.3x.

For a market leader with a 13% to 16% long-term expected EPS growth rate, a forward P/E of 17.3x is highly reasonable, especially compared to the broader S&P 500, which trades at a significantly higher multiple. However, some value-focused analysts have maintained a "Hold" rating, arguing that the valuation is fair but leaves limited room for multiple expansion given the industry-wide risks.

Key Risks to Monitor

• High Customer Concentration: McKesson operates in a highly consolidated market. Its largest customer, CVS Health, accounted for approximately 24% of the company’s consolidated revenues in fiscal 2026. McKesson’s top ten customers collectively represented 73% of total revenues. If CVS Health were to renegotiate its contracts at lower margins or divert a significant portion of its business elsewhere, McKesson’s financials would suffer a severe blow.
• The GLP-1 Double-Edged Sword: A significant portion of McKesson’s recent revenue growth has been fueled by the massive surge in demand for GLP-1 weight-loss and diabetes medications (like Ozempic and Wegovy). While these high-priced therapies inflate McKesson's top-line revenue numbers, they are actually lower-margin products for distributors. There is a risk that as GLP-1 pricing normalizes or as manufacturers bypass distributors to sell directly, McKesson's revenue growth could plateau while exposing lower margins in other segments.
• Regulatory and Drug-Pricing Reform: The U.S. healthcare system is under constant legislative scrutiny. Changes to the 340B drug pricing program, potential reforms from the Inflation Reduction Act (IRA), and modifications to Medicare and Medicaid reimbursement models could squeeze distribution margins. McKesson must continually adapt to a shifting regulatory landscape that targets drug pricing middle-men.
• Ongoing Litigation: Like its peers Cardinal Health and Cencora, McKesson has spent the last several years navigating costly legal disputes, most notably related to its historical role in the distribution of controlled substances (the opioid epidemic). While the company has structured long-term settlement payment plans that are fully factored into its cash flow models, any new systemic litigation represents a capital drain.

Frequently Asked Questions (FAQs)

Is McKesson stock a buy, hold, or sell in 2026?

For long-term investors focused on stable compounding, McKesson remains a Buy. The combination of high-single-digit organic growth, specialized oncology expansion, a massive $7.7 billion share buyback pipeline, and a highly reasonable forward P/E of 17.3x makes it a highly defensive compounder. However, conservative value investors may prefer to buy on pullbacks closer to $700 to secure a larger margin of safety.

Why is McKesson spinning off its Medical-Surgical Solutions segment?

McKesson is spinning off Medical-Surgical Solutions to unlock shareholder value. By separating the medical-surgical supply business from the core pharmaceutical and specialty care businesses, both companies can focus on their distinct strategic priorities. The spinoff also allows investors to value the high-margin oncology and biopharma business independently, which could lead to multiple expansion for the parent company.

What does the Apollo Global Management deal mean for McKesson stock?

Apollo’s $1.25 billion investment in a 13% minority stake in the Medical-Surgical Solutions segment values the division at $13 billion. This transaction acts as a major catalyst. It validates the hidden value in McKesson’s segments, provides immediate liquidity, and pairs the division with an experienced financial sponsor to navigate its upcoming IPO in 2027.

Will McKesson stock split in 2026?

While some financial analysts speculate that McKesson could be a candidate for a stock split due to its high share price (trading over $750), the company has not officially announced any stock split plans in 2026. McKesson’s last stock split was a 2-for-1 split in January 1998.

Conclusion: The Bottom Line on McKesson Stock

McKesson Corporation continues to prove why it is one of the most reliable wealth compounders in the healthcare sector. The company's stellar Fiscal 2026 results, showing a 12% revenue jump to $403.43 billion and an 18% surge in Adjusted EPS to $39.11, demonstrate the strength of its diversified healthcare model.

By executing surgical portfolio changes—including the complete divestiture of European retail operations and the highly lucrative $13 billion valuation milestone for its Medical-Surgical segment via the Apollo partnership—McKesson is transforming into a leaner, higher-margin specialty healthcare powerhouse. Supported by a defensive moat in oncology, an aggressive $7.7 billion stock repurchase program, and an incredibly safe, growing dividend, McKesson stock (MCK) represents a stellar combination of low volatility, reliable growth, and disciplined execution. For investors looking to fortify their portfolios in 2026, McKesson remains a premium blue-chip compounder that is well-positioned to deliver market-beating returns for years to come.